Benefits of Dual I-O Therapy in NSCLC and Malignant Pleural Mesothelioma

Mark A. Socinski, MD
Executive Medical Director
AdventHealth Cancer Institute
Orlando, FL

Dr Mark Socinski analyzes data from the CITYSCAPE and COAST studies showing improved ORR and PFS with combinations of novel immunotherapy agents in patients with metastatic or locally advanced/unresectable NSCLC, and from the CheckMate-743 study, in which the combination of nivolumab plus ipilimumab resulted in improved survival over chemotherapy in patients with malignant pleural mesothelioma.

Related Items

Conference Correspondent Coverage is Brought to You by the Publishers of:
Journal of Hematology Oncology Pharmacy
Journal of Oncology Navigation & Survivorship
Oncology Practice Management
Personalized Medicine in Oncology

Learn more about our family of publications.

View Our Publications